DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more

Stalevo (Carbidopa / Levodopa / Entacapone) - Summary



Stalevo® (carbidopa, levodopa and entacapone) is a combination of carbidopa, levodopa and entacapone for the treatment of Parkinson's disease.

Stalevo® (carbidopa, levodopa and entacapone) is indicated to treat patients with idiopathic Parkinson's disease:

  1. To substitute (with equivalent strength of each of the three components) for immediate-release carbidopa/levodopa and entacapone previously administered asindividual products.
  2. To replace immediate-release carbidopa/levodopa therapy (without entacapone) when patients experience the signs and symptoms of end-of-dose "wearing-off" (only for patients taking a total daily dose of levodopa of 600 mg or less and not experiencing dyskinesias, see DOSAGE AND ADMINISTRATION).

See all Stalevo indications & dosage >>


Media Articles Related to Stalevo (Carbidopa / Levodopa / Entacapone)

Drug discovery for Parkinson's disease: LCSB researchers grow neurons in 3-D
Source: Neurology / Neuroscience News From Medical News Today [2015.06.26]
The progressive loss of neurons in the brain of Parkinson's patients is slow yet inexorable. So far, there are no drugs that can halt this insidious process.

New study calls for partnering of Parkinson's disease research community with patient groups to improve effectiveness of clinical trials
Source: Clinical Trials / Drug Trials News From Medical News Today [2015.06.25]
Despite an urgent need for new medications, clinical trials in Parkinson's disease (PD) have a relatively low rate of success.

New knowledge: Parkinson's disease may begin in the gut
Source: GastroIntestinal / Gastroenterology News From Medical News Today [2015.06.24]
A major epidemiological registry-based study from Aarhus University and Aarhus University Hospital indicates that Parkinson's disease begins in the gastrointestinal tract; the study is the largest in...

New Med Reduces Psychosis in Parkinson's Disease Patients
Source: MedPage Today Psychiatry [2015.06.19]
(MedPage Today) -- Pimavanserin appears safe across multiple phase III trials

Phase III data released for NUPLAZID (pimavanserin) for Parkinson's disease psychosis
Source: Clinical Trials / Drug Trials News From Medical News Today [2015.06.18]
ACADIA Pharmaceuticals Inc., a biopharmaceutical company focused on innovative treatments that address unmet medical needs in neurological and related central nervous system disorders, have...

more news >>

Published Studies Related to Stalevo (Carbidopa / Levodopa / Entacapone)

Long-term outcome of early versus delayed rasagiline treatment in early Parkinson's disease. [2009.03.15]
The purpose of this study to compare the long-term clinical outcome of early versus delayed rasagiline treatment in early Parkinson's disease (PD). Subjects (N = 404) were randomly assigned to initial treatment with rasagiline (early-start group) or placebo for 6 months followed by rasagiline (delayed-start group) in the TEMPO study...

Entacapone prolongs the reduction of PLM by levodopa/carbidopa in restless legs syndrome. [2007.11]
OBJECTIVES: Levodopa is effective in the treatment of restless legs syndrome (RLS). However, due to the short duration of action of conventional levodopa/decarboxylase inhibitor formulations, multiple dosing may be required in individual patients with persisting symptoms. We assessed whether a new levodopa formulation containing levodopa, carbidopa, and entacapone (LCE) improves levodopa action in RLS... CONCLUSIONS: Single doses of LCE tablets decreased PLMs in a dose-related manner in RLS patients. Prolonged effects of levodopa on PLMs suggest that, compared with standard levodopa, this new levodopa formulation provides longer symptom control throughout the night in patients with previously untreated RLS.

Treatment of end-of-dose wearing-off in parkinson's disease: stalevo (levodopa/carbidopa/entacapone) and levodopa/DDCI given in combination with Comtess/Comtan (entacapone) provide equivalent improvements in symptom control superior to that of traditional levodopa/DDCI treatment. [2005]
The aim of this study was to evaluate the efficacy of the new optimised levodopa, Stalevo (levodopa, carbidopa and entacapone) in patients with Parkinson's disease experiencing end-of-dose wearing-off. Treatment with Stalevo was compared to treatment with traditional immediate-release levodopa and dopa-decarboxylase inhibitor (DDCI) formulations along with adjunct entacapone (Comtess/Comtan)...

Determination of L-dopa, carbidopa, 3-O-methyldopa and entacapone in human plasma by HPLC-ED. [2011.02.20]
The aim of the study was the development of analytical methods suitable for the quantification of L-dopa, carbidopa and entacapone in plasma of Parkinsonian patients treated with Stalevo((R)). The metabolite 3-O-methyldopa was also determined to obtain some indications on the pharmacokinetics of L-dopa...

[The effect of Stalevo-dosing on quality of life of Parkinsonian patients with wearing-off]. [2010.07.30]
In Stalevo tablets, used in the therapy of patients with Parkinson's disease, levodopa is combined with decarboxylase inhibitors and COMT inhibitors to provide a more steady plasma concentration of levodopa. Previously several study has shown, that the better pharmacokinetic profile decreases the fluctuation of motor and non-motor symptoms...

more studies >>

Clinical Trials Related to Stalevo (Carbidopa / Levodopa / Entacapone)

Study to Evaluate Initiation of Stalevo in Early Wearing-Off [Completed]
An open, non-randomised, multinational, multicentre direct switch study in levodopa-treated Parkinson's disease patients suffering from early wearing-off in Parkinson's disease. The study will consist of 2 consecutive periods: screening period and study treatment period. Duration of the study will be up to 8 weeks for each subject. The study treatment dosage will be determined by the subject's current, separately administered standard levodopa/DDCI treatment (3-4 doses per day, maximum of total daily dose of 600 mg levodopa) which will be switched to an equivalent dose of Stalevo« without changing the number of doses per day. The levodopa daily dose during Stalevo┬« treatment may be adjusted according to the study subject's clinical response.

Stalevo in Early Wearing-Off Patients [Active, not recruiting]
The purpose of this study is to demonstrate in patients with Parkinson's disease that, when compared to levodopa/carbidopa, Stalevo will delay the time from initiation of study drug to the time an increase in antiparkinsonian medication is required due to inadequately controlled parkinsonian symptoms.

PET-Study: Effects of Single Doses of Stalevo and Levodopa/Carbidopa on Striatal 11C-Raclopride Binding [Terminated]
This is an open, randomised, active-controlled, 2-period crossover study comparing the effect of single doses of Stalevo 200 and Sinemet on striatal (putamenal and caudate) 11C-raclopride BP in PD patients with wearing-off symptoms. The study consists of 4 visits: a screening visit (visit 1), 2 treatment periods (period 1=visit 2, period 2=visit 3) separated by a minimum wash-out period of at least 3 days, and an end-of-study visit (visit 4). Subjects will be randomly allocated to start the period 1 with a single dose of Stalevo 200 or Sinemet. After the wash-out the study drug on period 2 will be administered according to a crossover design.

Pharmacokinetic Study With Repeated Doses of Stalevo [Completed]
The purpose of this study is to show that higher minimum concentration values are obtained following repeated doses of Stalevo 4 times daily compared to lecodopa/carbidopa treatment with corresponding dosing regimen.

Adherence of Stalevo, Entacapone and Levodopa [Completed]
To test if combining two antiparkinson drugs into a single tablet improves accuracy of medicine intake by the patient.

To test if patients with Parkinson's disease who take medicines at regular time intervals have smoother symptom control.

more trials >>

Page last updated: 2015-06-26

-- advertisement -- The American Red Cross
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2015